Literature DB >> 2261844

Metabolic and health complications of obesity.

S M Grundy1, J P Barnett.   

Abstract

Overnutrition manifested by obesity has emerged as a major health problem in affluent countries. In spite of increased interest in fitness, obesity is on the increase in the United States. This is particularly so among children and adolescents. Although obesity is associated with many risk factors for diseases, the mechanisms whereby it enhances disease risk are not fully understood. Such an understanding is needed to develop strategies for management of these conditions. In this report we suggest that overnutrition produces clinical diseases only in individuals who already possess a metabolic weakness or "defect" in a given system. In the absence of such underlying defects, overnutrition, or obesity, is well tolerated. One of the most common consequences of obesity is dyslipidemia, that is, elevations of very low-density lipoprotein (VLDL) triglycerides and low-density lipoprotein (LDL) cholesterol and low concentrations of high-density lipoprotein (HDL) cholesterol. The major effect of overnutrition on lipoprotein metabolism is to stimulate the production of VLDL. For patients who have an underlying defect in lypolysis of VLDL triglycerides, hypertriglyceridemia will develop in the obese state. For those who have defective clearance of LDL, obesity will accentuate hypercholesterolemia. Both of these effects can be explained by overproduction of VLDL, due to obesity, combined with a genetic defect in clearance of VLDL or LDL. The mechanism whereby obesity causes a lowering of HDL cholesterol is uncertain, although it could enhance removal of HDL by an excess of adipose tissue. Another disease associated with obesity is cholesterol gallstones. The presence of obesity more than doubles the risk for gallstones. Two underlying factors increase the danger for gallstones: a deficiency of hepatic secretion of bile acids and a tendency for formation of cholesterol crystals in bile. Overnutrition promotes the synthesis of whole-body cholesterol, and the only route for excretion of this excess cholesterol is through the biliary tree.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261844

Source DB:  PubMed          Journal:  Dis Mon        ISSN: 0011-5029            Impact factor:   3.800


  31 in total

1.  Weight loss counseling by health care providers.

Authors:  H Nawaz; M L Adams; D L Katz
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

2.  Long term effects of ketogenic diet in obese subjects with high cholesterol level.

Authors:  Hussein M Dashti; Naji S Al-Zaid; Thazhumpal C Mathew; Mahdi Al-Mousawi; Hussain Talib; Sami K Asfar; Abdulla I Behbahani
Journal:  Mol Cell Biochem       Date:  2006-04-21       Impact factor: 3.396

Review 3.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

Review 4.  Cholecystectomy and risk of metabolic syndrome.

Authors:  Agostino Di Ciaula; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Eur J Intern Med       Date:  2018-04-26       Impact factor: 4.487

5.  Obesity: its epidemiology, comorbidities, and management.

Authors:  Jana Jarolimova; James Tagoni; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-03

6.  Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.

Authors:  P De Vos; A M Lefebvre; S G Miller; M Guerre-Millo; K Wong; R Saladin; L G Hamann; B Staels; M R Briggs; J Auwerx
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

7.  Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Authors:  Cesar A Santa-Maria; Amanda Blackford; Anne T Nguyen; Todd C Skaar; Santosh Philips; Steffi Oesterreich; James M Rae; Zeruesenay Desta; Jason Robarge; Norah Lynn Henry; Anna M Storniolo; Daniel F Hayes; Roger S Blumenthal; Pamela Ouyang; Wendy S Post; David A Flockhart; Vered Stearns
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 8.  Obesity cardiomyopathy and systolic function: obesity is not independently associated with dilated cardiomyopathy.

Authors:  Muhammad Fahad Khan; Mohammad Reza Movahed
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

9.  Anti-Obesity Agents and the US Food and Drug Administration.

Authors:  Martin F Casey; Jeffrey I Mechanick
Journal:  Curr Obes Rep       Date:  2014-09

10.  The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression.

Authors:  S G Miller; P De Vos; M Guerre-Millo; K Wong; T Hermann; B Staels; M R Briggs; J Auwerx
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.